Entry into a Material Definitive Agreement. On August 6, 2026, Aclaris Therapeutics, Inc. (the “Company”) entered into a Second Amended and Restated Sales Agreement (the “Amended ATM Agreement”) with Leerink Partners LLC (“Leerink”) and Cantor Fitzgerald & Co. (“Cantor”) under which the Company may offer and sell, from time to time at the Company’s sole discretion, shares of common stock through Leerink and Cantor as sales agents. The issuance and sale, if any, of common stock under the Amend…

and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by…

and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by…

and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by…

Other Events. Interim Phase 1a SAD/MAD Results The Interim Results announced in the press release are summarized below. The randomized, blinded, placebo-controlled Phase 1a portion of the SAD/MAD trial was designed to evaluate the safety, tolerability, pharmacokinetics (“ PK ”), and pharmacodynamics (“ PD ”) of subcutaneously administered ATI-052 in healthy adults receiving SAD and MAD. In the SAD portion, four cohorts of eight healthy volunteers each were randomized 3:1 to receive a single d…

and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by…

and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by…

Approval of a new equity incentive plan and related documents.

and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by…

and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by…

Unregistered Sales of Equity Securities. Warrants The Warrants have not been registered under the Securities Act of 1933, as amended (the “ Securities Act ”). The Warrants were issued pursuant to the exemption from registration provided by Regulation S adopted under the Securities Act for offers and sales to a non “U.S. Person” in an “Offshore Transaction”, as those terms are defined in Regulation S. Private Placement The Shares have not been registered under the Securities Act. Based in part…

Entry into a Material Definitive Agreement. Exclusive License Agreement, Collaboration Agreement and Warrants On November 18, 2024, Aclaris Therapeutics, Inc. (the “ Company ”) entered into an exclusive license agreement (the “ License Agreement ”) with Biosion, Inc. (“ Biosion ”), pursuant to which the Company received the exclusive, worldwide (excluding Mainland China, Macau, Hong Kong and Taiwan) (the “ Territory ”) rights to develop, manufacture and commercialize BSI-045B, an anti-TSLP mo…

President and Chief Operating Officer, Class III Director — Hugh Davis, PhD: Hugh Davis was appointed as President and Chief Operating Officer, and Class III Director.

and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by…

and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended (the “ Securities Act ”), or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except…

Entry into a Material Definitive Agreement. On July 16, 2024, Aclaris Therapeutics, Inc. (the “ Company ”) and OCM IP Healthcare Portfolio LP, an investment vehicle of OMERS, entered into a royalty purchase agreement (the “ Agreement ”) pursuant to which the Company sold to OMERS a portion of its future royalty payments and the remaining anniversary milestones associated with the Company’s existing license to Eli Lilly and Company (“ Lilly ”) relating to OLUMIANT® (baricitinib) for the treatm…

and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended (the “ Securities Act ”), or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except…

Director — Andrew Powell and Bryan Reasons: Both Andrew Powell and Bryan Reasons are resigning from the Board of Directors, with no disagreements noted.

and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended (the “ Securities Act ”), or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except…

Costs Associated with Exit or Disposal Activities. ​ On December 19, 2023, Aclaris Therapeutics, Inc. (the “ Company ”) announced a reduction of its workforce by approximately 46%, which the Company expects to be substantially completed by June 30, 2024, and fully completed by December 31, 2024. The Board of Directors approved these actions on December 18, 2023 in light of the Company’s revised operating plans, in order to streamline operations, reduce costs and preserve capital. ​ As a resul…

and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended (the “ Securities Act ”), or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except…

and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended (the “ Securities Act ”), or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except…

Chief Scientific Officer — Joseph Monahan: Dr. Monahan's role shifted to part-time status with a corresponding reduction in salary and bonus eligibility.

Entry into a Material Definitive Agreement. On May 26, 2023, Aclaris Therapeutics, Inc. (the “ Company ”) entered into an Office Lease (the “ Lease ”) with CBCC – Lee Road Acquisitions, LLC, a Delaware limited liability company (the “ Landlord ”), under which the Company will lease 11,564 square feet of space for its corporate headquarters to be located at 701 Lee Road, Wayne, Pennsylvania 19087. The term of the Lease is anticipated to commence on November 1, 2023 and expire on March 31, 2029…

and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended (the “ Securities Act ”), or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except…